Live Feeds
● LIVE Updated 10d ago · 17 sources tracked

Retraction of high-profile paper on cancer drug timing could hand ammo to China hawks

Nature Medicine retracted a February 2026 paper regarding a China-based lung cancer immunotherapy trial on June 24, 2026. The study had claimed that treatment timing, specifically early morning administration, improved survival rates. The journal cited concerns over data integrity following a four-month investigation.

RSS Source map (16)

What changed

A high-profile study on cancer drug timing was retracted due to data integrity issues.

Live updates

  1. Nature Medicine Retracts Chinese Lung Cancer Immunotherapy Timing Study

    Nature Medicine retracted a February 2026 paper regarding a China-based lung cancer immunotherapy trial on June 24, 2026. The study had claimed that treatment timing, specifically early morning administration, improved survival rates. The journal cited concerns over data integrity following a four-month investigation.

    What's confirmed:

    • Nature Medicine retracted a February 2026 paper on a China-based lung cancer immunotherapy trial on June 24, 2026.
    • The retracted study suggested that lung cancer survival was tied to the timing of treatment.
    • The retraction followed a four-month investigation.
    • The journal cited data integrity concerns for the retraction.

    Still unconfirmed:

    • The retraction could provide ammunition to China hawks.
    • The retraction is fueling US tensions.
    confidence 95%